Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine augmentation of intensive exposure therapy for pediatric obsessive-compulsive disorder
ACTRN12614000140651Phase 2Completed
- Sponsor
- Dr Lara Farrell
- Start
- Jan 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in obsessive compulsive disorder (OCD) (3 arms), sponsored by Dr Lara Farrell. Primary endpoint: Obsessive compulsive symptom severity. Started Jan 2014; status: completed.
02
Drugs
d-cycloserine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on ACTRN12614000140651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000140651.